PRPH Stock Overview
ProPhase Labs, Inc. engages in the development and commercialization of novel drugs, dietary supplements, and compounds in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
ProPhase Labs, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.36 |
| 52 Week High | US$12.69 |
| 52 Week Low | US$4.05 |
| Beta | -0.35 |
| 1 Month Change | -17.11% |
| 3 Month Change | -40.68% |
| 1 Year Change | -58.24% |
| 3 Year Change | 14.44% |
| 5 Year Change | 46.80% |
| Change since IPO | 772.00% |
Recent News & Updates
ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate
Sep 21
Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt
Aug 11Recent updates
ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate
Sep 21Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt
Aug 11We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease
Apr 07ProPhase Labs (NASDAQ:PRPH) Seems To Use Debt Quite Sensibly
Jan 24ProPhase Labs: Small Cap Stock With Strong Fundamentals And Growth Potential
Oct 13ProPhase Labs Q2 2022 Earnings Preview
Aug 10We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt
Jul 26ProPhase Labs to license two investigational cancer compounds from Global BioLife
Jul 21ProPhase Labs: A Stellar Quarter And Another Special Dividend
May 16ProPhase Labs (NASDAQ:PRPH) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Apr 08ProPhase Labs (NASDAQ:PRPH) Is Using Debt Safely
Mar 23Rock star Growth Puts ProPhase Labs (NASDAQ:PRPH) In A Position To Use Debt
Nov 30As Employer Vaccine Mandates Fail, Prophase Labs Could Benefit
Oct 20Calculating The Fair Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)
Jul 22ProPhase Labs Is A Potential Pure Play On Worries About The Delta And Delta Plus Covid-19 Variants
Jun 28Here's Why Shareholders May Consider Paying ProPhase Labs, Inc.'s (NASDAQ:PRPH) CEO A Little More
May 14ProPhase Labs partners with Dutchess County New York to provide COVID-19 testing
May 06A Look At The Intrinsic Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)
Apr 12ProPhase Labs opens Covid testing facility in New York
Jan 29ProPhase Labs announces $5.5M registered direct offering of common stock and warrants
Jan 05ProPhase Labs expands COVID-19 testing capacity in New York, shares +21%
Dec 09Subject, Verb, COVID-19: ProPhase Doesn't Deserve Its Recent Share Price Increase
Nov 10Shareholder Returns
| PRPH | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -4.0% | -2.0% | -2.7% |
| 1Y | -58.2% | 11.9% | 16.8% |
Return vs Industry: PRPH underperformed the US Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: PRPH underperformed the US Market which returned 15.1% over the past year.
Price Volatility
| PRPH volatility | |
|---|---|
| PRPH Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in US Market | 14.2% |
| 10% least volatile stocks in US Market | 2.5% |
Stable Share Price: PRPH is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: PRPH's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 129 | Ted Karkus | https://www.prophaselabs.com |
ProPhase Labs, Inc. engages in the development and commercialization of novel drugs, dietary supplements, and compounds in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It provides a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
ProPhase Labs, Inc. Fundamentals Summary
| PRPH fundamental statistics | |
|---|---|
| Market Cap | US$73.44m |
| Earnings (TTM) | -US$4.37m |
| Revenue (TTM) | US$78.54m |
0.9x
P/S Ratio-16.8x
P/E RatioIs PRPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRPH income statement (TTM) | |
|---|---|
| Revenue | US$78.54m |
| Cost of Revenue | US$38.32m |
| Gross Profit | US$40.23m |
| Other Expenses | US$44.59m |
| Earnings | -US$4.37m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.26 |
| Gross Margin | 51.21% |
| Net Profit Margin | -5.56% |
| Debt/Equity Ratio | 16.3% |
How did PRPH perform over the long term?
See historical performance and comparison